Silgan Holdings earnings date
Silgan Holdings (SL3) Q3 2026 Earnings Report
DE:SL3 Q3 2026 EPS Results
- Actual EPS
- EUR 1.17
- Consensus EPS
- EUR 1.12
- Beat/Miss
- Beat by +EUR 0.05
- One Year Ago EPS
- EUR 1.09
DE:SL3 Q3 2026 Revenue Results
- Actual Revenue
- EUR 1.83B
- Expected Revenue
- EUR 1.88B
- Beat/Miss
- Missed by -EUR 56.55M
- YoY Revenue Growth
- +1.57%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/29/2026
- Time
- Before Open
- Conference Call
- Thursday, October 29, 2026
Silgan Holdings's next earnings date is estimated for January 26, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive overall. Silgan reported record adjusted EPS, higher adjusted EBIT, increased full-year guidance, strong performance in fragrance, pharma, Metal Containers, and Custom Containers, and an expected increase in 2027 organic earnings and free cash flow. These positives outweighed challenges from weaker consumer demand, lower volumes in several categories, inflation, Brazil, and ongoing recovery timing for Dispensing margins.
For the fourth quarter of 2026, Silgan estimated adjusted earnings of $0.76 to $0.86 per diluted share versus adjusted EPS of $0.67 in the prior year period, with higher year-over-year adjusted EBIT of approximately $10 million to $15 million, interest expense of $45 million to $50 million, a tax rate of approximately 25% to 26%, and volumes comparable to prior year levels in all segments; Dispensing and Specialty Closures organic EBIT is expected to grow year-over-year in Q4. For full year 2026, Silgan increased adjusted EPS guidance to $3.83 to $3.93, a 4% increase at the midpoint versus $3.72 in 2025, including low single-digit percentage adjusted EBIT growth, adjusted corporate expense of approximately $45 million to $50 million, interest expense of approximately $185 million, an expected tax rate of 25% to 26%, and volumes comparable to the prior year period in all 3 segments; free cash flow is expected to be approximately $450 million, including CapEx of approximately $310 million. For 2027, Silgan expects another year of organic earnings and free cash flow growth, with some kind of modest free cash flow growth, while longer-term expectations include mid-single-digit growth in fragrance and beauty, probably closer to high single-digit growth in healthcare pharma, and low single digit growth in food and beverage.
- Record Third-Quarter Adjusted EPSSilgan delivered record third-quarter adjusted EPS of $1.31, up 7% from the prior-year period and at the high end of the company's estimated range. The result was driven by higher adjusted EBIT and lower interest expense, partially offset by a higher adjusted tax rate.
- Higher Sales and Adjusted EBITThird-quarter net sales were approximately $2 billion, up 2% year over year, primarily due to the pass-through of higher raw material and other costs. Total adjusted EBIT was $235 million, up 6% from the prior year, mostly due to higher adjusted EBIT in Metal Containers.
- Strategic Growth Initiatives Delivered Volume GainsYear to date, Silgan delivered mid-single-digit growth in fragrance dispensing products and in pet food and Metal Containers, while also seeing significant and growing interest in healthcare and pharma dispensing products.
- Full-Year Adjusted EPS Expectations RaisedThe company increased the midpoint of its full-year adjusted EPS range twice during 2026 despite a more challenging consumer demand environment and significant raw material and other cost inflation.
- Strong Fragrance and Pharma Dispensing PerformanceDispensing and Specialty Closures delivered another quarter of mid-single-digit growth in high-end fragrance products. Prescription pharma dispensing products continued to gain traction and grew by a double-digit percentage in North America.
- Planned Cost Recovery Actions in DispensingSilgan implemented actions during the third and fourth quarters to recover cost increases in Dispensing and Specialty Closures, including aggressive pricing actions where contractual pass-throughs did not cover other inflationary costs. Management expects these actions to offset much of the impact, with some recovery continuing into the first quarter.
- Metal Container Adjusted EBIT Increased 10%Metal Container adjusted EBIT grew 10% year over year, or $9 million above prior-year levels. Higher fruit and vegetable and wet pet food volumes, a more normalized 2026 volume cadence, streamlined operations, and favorable price-over-cost performance supported the improvement.
- Benefits from the Cost Reduction ProgramSilgan cited the benefits of its prior cost reduction initiative, which removed $50 million of cost from the overall operating network. Three facilities were closed last year, lowering operating costs, while improved planning for the fruit and vegetable pack enabled more efficient facility operations.
- Custom Containers Delivered Record Adjusted EBITCustom Containers generated another quarter of record adjusted EBIT. Sales increased 4% year over year, and favorable price-over-cost performance, including mix and cost savings from footprint optimization, more than offset lower volumes.
- Positive Fourth-Quarter Earnings OutlookFourth-quarter adjusted EPS is expected to range from $0.76 to $0.86 per diluted share versus $0.67 in the prior-year period. At the midpoint, the outlook assumes adjusted EBIT approximately $10 million to $15 million higher year over year, with volumes comparable to prior-year levels in all segments.
- Raised Full-Year 2026 Guidance and Free Cash Flow TargetFull-year 2026 adjusted EPS guidance was increased to $3.83-$3.93, representing a 4% increase at the midpoint versus $3.72 in 2025. The outlook includes low single-digit percentage adjusted EBIT growth and approximately $450 million of free cash flow, including approximately $310 million of capital expenditures.
- Favorable Interest and Corporate Expense PerformanceInterest expense was favorable to expectations in the third quarter due in part to global treasury initiatives focused mostly on cash repatriation and improved seasonal working capital management. Corporate expense, excluding announced acquisition costs, was approximately $6 million below the prior-year level, partly due to the reversal of corporate development costs associated with the Trivium acquisition.
- Fragrance Innovation and New Product WinsSilgan said it is winning a disproportionate amount of new high-end fragrance product launches through innovation, design capabilities, and customer partnerships. Management cited an example in which Silgan won 7 of 8 sprayers in a product family and expects mid-single-digit long-term growth in fragrance and beauty, including in 2027.
- Healthcare and Pharma Business Reaching Approximately $250 MillionHealthcare and pharma dispensing is expected to be a roughly $250 million total revenue business for Silgan in 2026. The company described it as one of its fastest-growing businesses, with significant development and regulatory pipelines typically spanning 3 to 5 years.
- Custom Containers Positioned for Longer-Term GrowthSilgan completed its Custom Containers footprint optimization in the fourth quarter of 2025 and is cycling over it for the final time in the fourth quarter of 2026. Management expects a steady-state comparison in 2027 and said the business is positioned for longer-term growth while maintaining the margin rates achieved through its improvement program.
- Proposed Trivium Transaction and New Operating StructureThe proposed acquisition of Trivium is expected to close in mid-2027 and would establish Silgan MCC and Silgan DS as two packaging companies. Management expects another year of organic earnings and free cash flow growth in 2027 and said the transaction is designed to be leverage-neutral to Silgan, with Dispensing Solutions expected to have approximately 1.8x leverage at inception.
- Continued Investment in Future GrowthSilgan plans to continue investing in products, operating facilities, people, and teams to prepare for the Trivium transaction and future growth. Management also said investments for 2027 fragrance product launches have already been made, while launches being discussed for 2028 and 2029 will require additional investment as part of normal capital expenditure requirements.
- Expected 2027 Free Cash Flow GrowthManagement expects free cash flow to grow in 2027, describing the anticipated increase as modest and dependent on volume growth, working capital initiatives, and continued focus on capital expenditures.
DE:SL3 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Jan 26, 2027 | 2026 (Q4) | 0.72- | 0.6 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | 1.121.17 | 1.09 | 7.38% (+0.08) | |
| Jul 29, 2026 | 2026 (Q2) | 0.860.88 | 0.9 | -2.97% (-0.03) | |
| Apr 29, 2026 | 2026 (Q1) | 0.670.70 | 0.73 | -4.88% (-0.04) | |
| Feb 04, 2026 | 2025 (Q4) | 0.570.60 | 0.76 | -21.18% (-0.16) | |
| Oct 29, 2025 | 2025 (Q3) | 1.091.09 | 1.08 | 0.83% (+0.01) | |
| Jul 30, 2025 | 2025 (Q2) | 0.920.90 | 0.79 | 14.77% (+0.12) | |
| Apr 30, 2025 | 2025 (Q1) | 0.700.73 | 0.62 | 18.84% (+0.12) | |
| Jan 29, 2025 | 2024 (Q4) | 0.730.76 | 0.56 | 34.92% (+0.20) | |
| Oct 30, 2024 | 2024 (Q3) | 1.101.08 | 1.04 | 4.31% (+0.04) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

